Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial
WILLIAM J. STEWART, MD
Dr. Stewart is a cardiologist at the Cleveland Clinic and a site co-principal investigator in the Post-CABG trial.
BYRON J. HOOGWERF, MD
Dr. Hoogwerf is a staff endocrinologist at the Cleveland Clinic and the site principal investigator in the Post-CABG trial. For a complete listing of trial investigators see reference 1.
The Post Coronary Artery Bypass Graft trial is an important milestone that documents the benefits of treating hypercholesterolemia in patients with severe coronary atherosclerosis who have had bypass surgery. In the present article, w e highlight the rationale, study design, and results of the Post-CABG study, which was recently published in the New England Journal of Medicine.